Letter: when to withhold anti‐TNF agents prior to abdominal surgery in patients with Crohn’s disease—the jury might still be out. Authors’ reply
- 30 July 2019
- journal article
- letter
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 50 (4) , 465-466
Abstract
Linked ContentThis article is linked to Lin et al and Gates papers. To view these articles, visit https://doi.org/10.1111/apt.15184 and https://doi.org/10.1111/apt.15384.Keywords
This publication has 6 references indexed in Scilit:
- Letter: when to withhold anti‐TNF agents prior to abdominal surgery in patients with Crohn's disease—the jury might still be outAlimentary Pharmacology & Therapeutics, 2019
- Systematic review with meta‐analysis: risk of post‐operative complications associated with pre‐operative exposure to anti‐tumour necrosis factor agents for Crohn’s diseaseAlimentary Pharmacology & Therapeutics, 2019
- Anti-TNF Therapy in Crohn’s DiseaseInternational Journal of Molecular Sciences, 2018
- Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trialThe Lancet Gastroenterology & Hepatology, 2017
- Step-up vs top-down therapy for Crohn's disease: medicine vs surgeryNature Reviews Gastroenterology & Hepatology, 2017
- Inhibition of tumor necrosis factor‐α attenuates wound breaking strength in ratsWound Repair and Regeneration, 2000